Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

India's Natco Joins the March to China's Market by Indian Pharmas

publication date: Aug 16, 2019

India's Natco Pharma, a company that specializes in complex generics, plans to build up its business in China, taking advantage of China's speeded-up approval process to register products that are already approved elsewhere. Natco has decided to diversify away from the US and de-risk its strategy by emphasizing markets such as China, Brazil and Canada. Natco will now spend about 60%-70% of its R&D investment in developing countries, leaving just 30% for the US. By making the change, Natco joins other India pharmas, Cipla and Sun Pharma, who have also announced China plans. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital